# A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Source: https://onco.cc/trials/nct07059221/  
OnCo record `nct07059221` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-A2102, Adebrelimab, Cetuximab in head and neck squamous cell carcinoma, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer is a phase 1/2 interventional study registered as NCT07059221 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 210 participants planned, started 2025-07-11 and due to reach its primary completion in 2027-03. Interventions recorded: SHR-A2102, Adebrelimab, Cetuximab, SHR-9839(sc), Carboplatin / Cisplatin. Conditions listed: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07059221
- Phase: 1/2
- Setting: A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT07059221: https://clinicaltrials.gov/study/NCT07059221

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07059221.json